- Home
- ZNTL vs ABOS Comparison
ZNTL vs ABOS Comparison
Compare ZNTL & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNTL | ABOS |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | 52 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.3M | 114.5M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | ABOS |
|---|---|---|
| Price | $2.97 | $1.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $5.87 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 2.6M | 220.8K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $26,865,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $0.86 |
| 52 Week High | $3.95 | $2.46 |
Technical Indicators
Market Signals| Indicator | ZNTL | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 66.51 | 48.18 |
| Support Level | $1.31 | $1.67 |
| Resistance Level | $3.95 | $2.39 |
| Average True Range (ATR) | 0.37 | 0.14 |
| MACD | 0.14 | -0.02 |
| Stochastic Oscillator | 62.50 | 48.94 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.